MedTrace Logo

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

NCT00349453 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-12-12

No results posted yet for this study

Summary

Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine

Conditions

  • Hemochromatosis

Interventions

DRUG

Deferiprone (L1)

50-100 mg/kg body weight daily

DRUG

Deferiprone (L1)

75 mg/kg body weight daily

DRUG

Desferrioxamine

35-50 mg/kg body weight on 2 or more days per week

Sponsors & Collaborators

  • Lipomed

    lead INDUSTRY

Principal Investigators

  • Petrign FG Töndury, MD

  • Markus Schmugge Liner, MD · University Children's Hospital, Zurich

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349453 on ClinicalTrials.gov